408 related articles for article (PubMed ID: 35578198)
1. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
[TBL] [Abstract][Full Text] [Related]
2. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
Feng Z; Shao D; Cai Y; Bi R; Ju X; Chen D; Song C; Chen X; Li J; An N; Li Y; Zhou Q; Xiu Z; Zhu S; Wu X; Wen H
J Ovarian Res; 2023 Mar; 16(1):53. PubMed ID: 36922847
[TBL] [Abstract][Full Text] [Related]
3. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
5. Clinical assays for assessment of homologous recombination DNA repair deficiency.
Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
[TBL] [Abstract][Full Text] [Related]
6. Biomarker Assessment of HR Deficiency, Tumor
Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
[TBL] [Abstract][Full Text] [Related]
7. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Cadoo K; Simpkins F; Mathews C; Liu YL; Provencher D; McCormick C; ElNaggar AC; Altman AD; Gilbert L; Black D; Kabil N; Bennett J; Munley J; Aghajanian C
Gynecol Oncol; 2022 Sep; 166(3):425-431. PubMed ID: 35803835
[TBL] [Abstract][Full Text] [Related]
8. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M
Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896
[TBL] [Abstract][Full Text] [Related]
9. RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With Prostate Cancer.
Brown LC; Zhu J; Mauer E; Thiede SN; Macera L; Stein MM; Taxter T; Raghavan D; Burgess EF
JCO Precis Oncol; 2023 Sep; 7():e2300378. PubMed ID: 38061006
[TBL] [Abstract][Full Text] [Related]
10. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
[TBL] [Abstract][Full Text] [Related]
11. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
Pellegrino B; Herencia-Ropero A; Llop-Guevara A; Pedretti F; Moles-Fernández A; Viaplana C; Villacampa G; Guzmán M; Rodríguez O; Grueso J; Jiménez J; Arenas EJ; Degasperi A; Dias JML; Forment JV; O'Connor MJ; Déas O; Cairo S; Zhou Y; Musolino A; Caldas C; Nik-Zainal S; Clarke RB; Nuciforo P; Díez O; Serres-Créixams X; Peg V; Espinosa-Bravo M; Macarulla T; Oaknin A; Mateo J; Arribas J; Dienstmann R; Bellet M; Oliveira M; Saura C; Gutiérrez-Enríquez S; Balmaña J; Serra V
Cancer Res; 2022 Apr; 82(8):1646-1657. PubMed ID: 35425960
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
[TBL] [Abstract][Full Text] [Related]
13. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Takaya H; Nakai H; Takamatsu S; Mandai M; Matsumura N
Sci Rep; 2020 Feb; 10(1):2757. PubMed ID: 32066851
[TBL] [Abstract][Full Text] [Related]
14. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
[No Abstract] [Full Text] [Related]
15. Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.
Pikkusaari S; Tumiati M; Virtanen A; Oikkonen J; Li Y; Perez-Villatoro F; Muranen T; Salko M; Huhtinen K; Kanerva A; Koskela H; Tapper J; Koivisto-Korander R; Joutsiniemi T; Haltia UM; Lassus H; Hautaniemi S; Färkkilä A; Hynninen J; Hietanen S; Carpén O; Kauppi L
Clin Cancer Res; 2023 Aug; 29(16):3110-3123. PubMed ID: 36805632
[TBL] [Abstract][Full Text] [Related]
16. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
[TBL] [Abstract][Full Text] [Related]
18. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
19. Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid.
Roussel-Simonin C; Blanc-Durand F; Tang R; Vasseur D; Le Formal A; Chardin L; Yaniz E; Gouy S; Maulard A; Scherier S; Sanson C; Lacroix L; Cotteret S; Mauny L; Zaccarini F; Rouleau E; Leary A
Mol Cancer; 2023 Nov; 22(1):178. PubMed ID: 37932736
[TBL] [Abstract][Full Text] [Related]
20. Structural Variants at the
Ewing A; Meynert A; Churchman M; Grimes GR; Hollis RL; Herrington CS; Rye T; Bartos C; Croy I; Ferguson M; Lennie M; McGoldrick T; McPhail N; Siddiqui N; Dowson S; Glasspool R; Mackean M; Nussey F; McDade B; Ennis D; McMahon L; Matakidou A; Dougherty B; March R; Barrett JC; McNeish IA; ; Biankin AV; Roxburgh P; Gourley C; Semple CA
Clin Cancer Res; 2021 Jun; 27(11):3201-3214. PubMed ID: 33741650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
